Results 151 to 160 of about 6,540 (205)

Special Diet for Familial Type II Hyperlipoproteinemia

Archives of Pediatrics & Adolescent Medicine, 1974
A suggested diet containing less than 200 mg cholesterol per day, with a polyunsaturate: saturate ratio of 0.9:1 was prepared for young children with familial hypercholesterolemia. A representative meal plan and calculations for a seven-day food intake allow for a practical, economical diet, low in cholesterol and saturated fat, but high in essential ...
R, Larsen, C J, Glueck, R, Tsang
openaire   +2 more sources

Therapeutic failure in familial type II hyperlipoproteinemia

Metabolism, 1976
The extended use of diet and cholestyramine therapy in familial type II hyperlipoproteinemia was examined in patients who previously participated in a short-term, double-blind trial. A striking secondary failure in therapeutic response during 4 yr of use of this therapy was noted with plasma cholesterol rising an average of 15%.
L A, Witters, P N, Herbert, R S, Shulman, R M, Krauss, R I, Levy   +4 more
openaire   +2 more sources

Sitosterol in Type II Hyperlipoproteinemia

1976
In 1951, PETERSON reported that the increase of plasma cholesterol levels in chickens caused by cholesterol feeding can be prevented by including 1 % soybean sterols in the diet (18). Since then, numerous investigators have demonstrated a hypocholesterolemic action of plant sterols, especially beta-sitosterol, in experimental animals and man (2, 3, 7 ...
P. Oster, G. Schlierf, C. Heuck, H. Greten, U. Gundert-Remy, W. Haase, G. Klose, A. Nothelfer, H. Raetzer, B. Schellenberg   +9 more
openaire   +1 more source

Pseudohomozygous and Pseudoheterozygous Type II Hyperlipoproteinemia

Archives of Pediatrics & Adolescent Medicine, 1976
A 4-year-old boy had typical features of homozygous type II hyperlipoproteinemia with planar xanthomas, a plasma cholesterol level greater than 600 mg/dl, and an estimated beta-lipoprotein cholesterol concentration greater than 500 mg/dl. Both he and his sister, who had the biochemical features of the heterozygous state, responded unusually well to a ...
openaire   +2 more sources

Treatment of type II hyperlipoproteinemia with d-thyroxine

Atherosclerosis, 1976
The effectiveness of a new, almost l-thyroxine free preparation of d-thyroxine (Dynothel) was tested in 15 patients with Type IIa and 4 patients with Type IIb hyperlipoproteinemia. Eleven patients with Type IIa and 3 with Type IIb were responsive to treatment and showed an average 26% decrease in plasma TC. This decrement in plasma TC was mirrored in a
A D, Rakow, H U, Klor, E, Kuter, H H, Ditschuneit, H, Ditschuneit   +4 more
openaire   +2 more sources

Results of colestipol therapy in type II hyperlipoproteinemia

Atherosclerosis, 1976
Twenty-five patinets with well defined Type ii hyperlipoproteinemia were treated with a divided 15 g daily dose of colestipol, a bile acid sequestrant, for periods of up to 20 months. The patients were divided into 3 groups: Those with no obvious sequelae, those with arcus corneae, xanthomas, and/or xanthelasmas only, and those with atherosclerotic ...
A M, Lees, M A, McCluskey, R S, Lees
openaire   +2 more sources

Homozygous Type II Hyperlipoproteinemia Treatment

JAMA, 1974
Dietary treatment was minimally effective in two children with homozygous type II hyperlipoproteinemia who had no evidence of atherosclerosis. Neither patient could tolerate cholestyramine resin in therapeutic doses. A partial ileal bypass operation was performed on each child, aged 10 and 8 years old.
openaire   +1 more source

Controlled trial of acifran in type II hyperlipoproteinemia

Clinical Pharmacology and Therapeutics, 1985
The hypolipidemic effects of acifran were evaluated in a randomized, double-blind, placebo-controlled study of 30 patients with type IIa hyperlipoproteinemia. Plasma lipid and lipoprotein values were determined at baseline (mean of three values), again after a 2-week single-blind period of acifran dosing, and at 2-week intervals during a 10-week period
D B, Hunninghake, K D, Edwards, G S, Sopko, R L, Tosiello   +3 more
openaire   +2 more sources

Neomycin and plasma lipoproteins in type II hyperlipoproteinemia

Clinical Pharmacology and Therapeutics, 1984
Neomycin, a nonabsorbable aminoglycoside antibiotic, has been shown to exert a hypocholesterolemic effect in man. In a 9-mo, double-blind, randomized, crossover, placebo-controlled clinical trial, the effect of neomycin, 2 gm/day, on plasma lipoproteins, as well as its safety, was described in 20 subjects with type II hyperlipoproteinemia. A 15% (50 mg%
Jeffrey M Hoeg, Ernst J Schaefer, Carol A Romano, Ernestina Bou, Anita M Pikus, Loren A Zech, Kent R Bailey, Richard E Gregg, Peter W F Wilson, Dennis L Sprecher, Alison M Grimes, Nancy G Sebring, Elaine J Ayres, Claus E Jahn, H B Brewer   +14 more
openaire   +2 more sources

Secondary type II hyperlipoproteinemia in patients with anorexia nervosa

Metabolism, 1978
In 18 patients with anorexia nervosa, plasma cholesterol and triglyceride concentral concentrations were repeatedly determined over a period of 14 mo. In 11 patients elevated cholesterol concentrations were found which were due to an increase of low-density lipoprotein cholesterol, whereas high-density lipoprotein and very low density lipoprotein ...
R, Mordasini, G, Klose, H, Greten
openaire   +2 more sources